Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 19;5(3):e0004312.
doi: 10.1371/journal.pgph.0004312. eCollection 2025.

Disparities in anti-SARS-CoV-2 reactivity according to vaccines administered in the era of omicron in Cameroon: Lessons for future outbreak response

Ezechiel Ngoufack Jagni Semengue  1 , Desire Takou  1 , Marina Potesta  2 , Sandrine Claire Ndjeyep Djupsa  1 , Carla Montesano  2   3 , Collins Ambes Chenwi  1   4 , Grace Beloumou  1 , Alex Durand Nka  1 , Aurelie Minelle Kengni Ngueko  1   4 , Evariste Molimbou  1   3   4 , Naomi-Karell Etame  1   5 , Davy-Hyacinthe Gouissi Anguechia  1   5 , Audrey Rachel Mundo Nayang  1 , Pamela Patricia Tueguem  1 , Therese Ndomgue  1   2 , Derrick Tambe Ayuk Ngwese  1   5 , Larissa Gaëlle Moko Fotso  1   5 , Carlos Michel Tommo Tchouaket  1   6 , Aude Christelle Ka'e  1   4 , Nadine Fainguem  1 , Cyrille Alain Abega Abega  1 , Nadia Mandeng  7   8   9 , Emilienne Epee  5   8   9 , Linda Esso  8   9 , Georges Etoundi Mballa  8   9 , Maria Mercedes Santoro  4 , Anne-Cecile Z-K Bissek  10 , John Otokoye Otshudiema  11 , Claudia Alteri  12 , Yap Boum Ii  5   8   9 , Anne-Geneviève Marcelin  13 , Francesca Ceccherini-Silberstein  4 , Alexis Ndjolo  1   5 , Carlo-Federico Perno  1   14 , Jean Kaseya  15 , Vittorio Colizzi  1   3 , Nicaise Ndembi  15   16 , Joseph Fokam  1   8   17
Affiliations

Disparities in anti-SARS-CoV-2 reactivity according to vaccines administered in the era of omicron in Cameroon: Lessons for future outbreak response

Ezechiel Ngoufack Jagni Semengue et al. PLOS Glob Public Health. .

Abstract

With the advent of COVID-19, anti-SARS-CoV-2 vaccines were a global health priority, but evidence on their significance within tropical settings remained limited. We sought to assess the distribution of anti-SARS-CoV-2 antibodies according to vaccine status and types of vaccines administered in Cameroon during Omicron waves. A community based cross-sectional sero-survey was conducted from February-15 through July-31 2022 among individuals tested for COVID-19 in Yaoundé-Cameroon. Sociodemographic data were collected from participants. Anti-SARS-CoV-2 antibodies (both IgG and IgM) were tested on plasma and statistical analyses were performed wherever appropriate. Logistic regression was done with p<0.05 considered statistically significant. Overall, 2449 participants were enrolled: median-age was 40 [31-49], 56.4% (1382/2449) men, 2.2% (54/2449) with flu-like symptoms and 19.6% (481/2449) reporting previous SARS-CoV-2 positivity. Regarding COVID-19 vaccination, 67.5% (1652/2449) had received at least one dose, 55.0% (909/1652) two-dose series and 37.1% (613/1652) received additional booster doses. Median duration from vaccination to phlebotomy was 5 [4-9] months. Seroprevalence of anti-SARS-CoV-2 antibodies was 81.1% (1987/2449). Following logistic regression, vaccine status (aOR=1.95), booster doses (aOR=1.36), post-vaccination time (≤5 months; aOR=1.64), Pfizer (aOR=2.07) and Moderna (aOR=1.52) vaccines, were all associated with a high prevalence of anti-SARS-CoV-2 antibodies (all p<0.05). This high seroprevalence of anti-SARS-CoV-2 antibodies suggests a certain degree of immunity/protection at community-level in Cameroon during Omicron waves, with Pfizer and Moderna inducing greater immunogenicity. However, rapid antibody waning (~5 months) calls for vaccine updates with novel variants (arising from a rapidly evolving virus) that could compromise already acquired immunity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no existing conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

    1. Nwosu K, Fokam J, Wanda F, Mama L, Orel E, Ray N, et al.. SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon. Nat Commun. 2021;12(1):5851. doi: 10.1038/s41467-021-25946-0 - DOI - PMC - PubMed
    1. Ndembi N, Aluso A, Habtemariam MK, Tsague L, Mwaba G, Muktar A, et al.. African leadership is critical in responding to public health threats. Nat Commun. 2024;15(1):877. doi: 10.1038/s41467-024-45220-3 - DOI - PMC - PubMed
    1. World Health Organization (WHO). Origin of SARS-CoV-2. 2020. [cited 29 Dec 2022]. Available from: https://www.who.int/publications/i/item/origin-of-sars-cov-2
    1. Nations Unies Cameroun. Plan de réponses socio-économiques des NU contre la Covid-19. [cited 25 Aug 2023]. Available from: https://unsdg.un.org/sites/default/files/2020-07/CMR_Socioeconomic-Respo...
    1. COVID-19: Cameroon adopts 3T strategy but emergency fund remains cloudy - Good Governance Africa. [cited 25 Aug 2023]. Available from: https://gga.org/covid-19-cameroon-adopts-3t-strategy-but-emergency-fund-...